$217.42 Million in Sales Expected for American Renal Associates Holdings Inc (NYSE:ARA) This Quarter

Wall Street brokerages predict that American Renal Associates Holdings Inc (NYSE:ARA) will post $217.42 million in sales for the current quarter, Zacks reports. Two analysts have issued estimates for American Renal Associates’ earnings, with estimates ranging from $217.24 million to $217.60 million. The company is expected to report its next earnings report on Tuesday, February 4th.

On average, analysts expect that American Renal Associates will report full-year sales of $833.84 million for the current financial year, with estimates ranging from $833.68 million to $834.00 million. For the next financial year, analysts anticipate that the business will post sales of $876.69 million, with estimates ranging from $875.37 million to $878.00 million. Zacks Investment Research’s sales calculations are a mean average based on a survey of sell-side research analysts that follow American Renal Associates.

American Renal Associates (NYSE:ARA) last issued its quarterly earnings data on Tuesday, November 5th. The company reported $0.33 earnings per share for the quarter, topping the consensus estimate of ($0.04) by $0.37. American Renal Associates had a negative net margin of 1.75% and a positive return on equity of 23.16%. The business had revenue of $211.43 million during the quarter, compared to the consensus estimate of $215.06 million.

Several brokerages recently commented on ARA. SunTrust Banks lifted their price target on shares of American Renal Associates from $7.00 to $12.00 and gave the stock a “hold” rating in a research note on Tuesday, September 10th. ValuEngine downgraded shares of American Renal Associates from a “strong-buy” rating to a “buy” rating in a research note on Thursday, November 14th. Seven investment analysts have rated the stock with a hold rating and one has issued a buy rating to the stock. American Renal Associates has an average rating of “Hold” and a consensus price target of $11.25.

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the business. Morgan Stanley lifted its stake in American Renal Associates by 68.5% in the second quarter. Morgan Stanley now owns 5,932 shares of the company’s stock valued at $44,000 after buying an additional 2,412 shares during the last quarter. Northern Trust Corp grew its position in shares of American Renal Associates by 2.5% during the second quarter. Northern Trust Corp now owns 175,543 shares of the company’s stock worth $1,306,000 after acquiring an additional 4,314 shares during the last quarter. Adams Diversified Equity Fund Inc. grew its position in shares of American Renal Associates by 24.7% during the second quarter. Adams Diversified Equity Fund Inc. now owns 22,239 shares of the company’s stock worth $165,000 after acquiring an additional 4,400 shares during the last quarter. California Public Employees Retirement System grew its position in shares of American Renal Associates by 7.0% during the third quarter. California Public Employees Retirement System now owns 91,266 shares of the company’s stock worth $577,000 after acquiring an additional 5,946 shares during the last quarter. Finally, Panagora Asset Management Inc. acquired a new position in shares of American Renal Associates in the 2nd quarter valued at $47,000. 85.40% of the stock is currently owned by institutional investors.

Shares of NYSE ARA traded up $0.23 during mid-day trading on Monday, reaching $9.43. The company had a trading volume of 122,147 shares, compared to its average volume of 209,647. The company has a current ratio of 1.01, a quick ratio of 0.97 and a debt-to-equity ratio of 8.05. The firm has a 50 day simple moving average of $8.54 and a two-hundred day simple moving average of $7.40. American Renal Associates has a 52-week low of $5.48 and a 52-week high of $16.62.

American Renal Associates Company Profile

American Renal Associates Holdings, Inc operates as a dialysis services provider in the United States. It operates dialysis clinics focusing on joint venture partnerships with physicians. The company offers kidney dialysis services to patients suffering from chronic kidney failure or end stage renal disease.

See Also: Retained Earnings

Get a free copy of the Zacks research report on American Renal Associates (ARA)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for American Renal Associates (NYSE:ARA)

Receive News & Ratings for American Renal Associates Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for American Renal Associates and related companies with MarketBeat.com's FREE daily email newsletter.